Publications by authors named "Kenichi Hanioka"
Drug-induced liver injury (DILI) results in the termination of drug development or withdrawal of a drug from the market. The establishment of a predictive, high-throughput preclinical test system to evaluate potential clinical DILI is therefore required. Here, we established a high content analysis (HCA) assay in human hepatocyte cell lines such as the HepaRG with normal expression levels of CYP enzymes and HepG2 with extremely low expression levels of CYP enzymes.
View Article and Find Full Text PDFArticle Synopsis
- The study assessed the antidiabetic effects of a new compound, FK614, in comparison with existing medications like rosiglitazone and pioglitazone, using diabetic mice models.
- FK614 demonstrated comparable effectiveness in reducing blood sugar and significantly improved triglyceride levels, particularly in db/db mice, highlighting its strong therapeutic potential.
- While FK614 activated PPARgamma similar to thiazolidinedione drugs, it showed a lower maximum effect, and toxicity studies indicated it may have a safer profile than rosiglitazone, suggesting FK614 could be a promising candidate for type 2 diabetes treatment.